Fig. 2: DEA on whole-blood mRNA levels of LRRK2 interactors in the sPD cases vs. Controls. | npj Parkinson's Disease

Fig. 2: DEA on whole-blood mRNA levels of LRRK2 interactors in the sPD cases vs. Controls.

From: Transcriptomics and weighted protein network analyses of the LRRK2 protein interactome reveal distinct molecular signatures for sporadic and LRRK2 Parkinson’s Disease

Fig. 2

A The scatter plot shows results from DEA performed on LRRK2 interactors; sPD cases vs. Controls. Interactors with significant alterations (|log2FC| > 0.05 and adjusted-p < 0.05) are colour coded as blue (down-regulated) and red (up-regulated) dots. B, C The bubble graphs show the enriched GO-BPs for up-regulated and down-regulated LRRK2 interactors; sPD cases vs. Controls. The colour of the bubble represents enrichment significance (−log10(adjusted-p)), while bubble size represents enrichment ratio (intersection size/query size). Of note, for up-regulated interactors, only top 20 GO-BPs are shown in the graph.

Back to article page